Envision Report

Published January 22, 2018

Asia Pacific Biosimilar Market – Size, Outlook, Trends and Forecasts (2018 – 2024)

Download Free Sample Report!

Biosimilar or follow-on-biologics are similar to the brand biopharmaceutical drugs which are synthetic versions of original products. Biosimilars have a patent expiration, and their developments are the crucial part of the overall growth of biosimilar market.  Biosimilars are derived from yeast, animals, bacteria, plants, and viruses.

Asia Pacific Biosimilars Market Segments Size & Growth:

Asia Pacific Biosimilars Market is accounted for $ XX billion in 2017 and expected to grow at a CAGR of XX% to reach $XX billion by 2024 during the forecast period 2018-2024. Major factors that are driving the market growth are next-gen business, high growth in chronic diseases, and less cost biosimilar drugs. However, high initial investments in research hinder the growth of the protein expression market.

Asia Pacific Biosimilars Market Segments Share:

Asia Pacific Biosimilars Market is categorised into by-product which consists of insulin, interferon, human growth hormone, and granulocyte colony-stimulating factor. Granulocyte colony-stimulating factor has the most significant share as they are cheaper compared to others. By services, Asia Pacific biosimilars market is segmented into clinical trials and contract research and manufacturing services. Among all clinical trials are expected to have high growth rate during the forecast period 2018-2024, due to increase in demand for low-cost drugs and vaccines that can treat various chronic diseases. The technology is segregated into chromatography, recombinant DNA technology, monoclonal antibodies technology, and nuclear magnetic resonance technology. Monoclonal antibodies technology is expected to have the most significant share in the market due to treating chronic diseases in a single operation

Blood disorders and autoimmune disease are leading in biosimilars among applications owing to the change in patent scenario and high-rated biologics. By Geography, China is dominating the biosimilars market, and the growth in the Asia Pacific is mainly attributed because of the favourable government’s regulations. Furthermore, India is witnessing the fastest growth during the forecast period, due to rising chronic diseases, adoption of biosimilar drugs and investment in R&D research.

Asia Pacific Biosimilars Market Segments Trends:

  • Emerging technology in biosimilars market is stem cell technology in Asia Pacific region.
  • In a recent study, biosimilar drugs will cut down the cost of biologics which helps in treating diseases like cancer and other chronic disorders intern replace the biologics in the market.
  • In January 2018, Novartis and Biocon have developed their biosimilar drug for the next generation in immunology and oncology.

Asia Pacific Biosimilars Research Report:

An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.

To have complete market analysis, industry value chain analysis, Porter’s Five Force Analysis, PESTLE, SWOT analysis, and Y-o-Y analysis were carried to understand the market more comprehensively.

Regional and global diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year-On-Year

Identifying DROC in the current market and their impact in altering the market dynamics.

Competitive landscape analysis to identify the mergers and acquisitions which will have a comparative financial study with significant competitors.

Expertise investment opportunities by an analyst to the individual and organisation to have a better foothold in the market.

  • Hexal
  • Zydus Cadila Healthcare
  • Novartis/Sandoz
  • Apotex
  • Samsung Bioepis

Chapter 1 Introduction

1.1 Executive Summary

1.2 Market Definition

1.3 Scope of the Study

Chapter 2 Research Methodology

2.1 Secondary Research

2.2 Primary Research

2.3 Analytic Tools and Model

2.4 Economic Indicator

2.4.1 Base Year, Base Currency, Forecasting Period

2.5 Expert Validation

2.6 Study Timeline

Chapter 3 Market Analysis

3.1 Industry Value Chain Analysis

3.2Porter’s Five Force Analysis

3.2.1 Bargaining Power of Buyers

3.2.2 Bargaining Power of Suppliers

3.2.3 Threats of Substitutes

3.2.4 Threats of New Entrants

3.2.5 Industry Rivalry

3.3 PESTLE Analysis

3.3.1 Political

3.3.2 Economical

3.3.3 Social

3.3.4 Technological

3.3.5 Legal

3.3.6 Environmental

3.4 SWOT Analysis

3.4.1 Strengths

3.4.2 Weakness

3.4.3 Opportunities

3.4.4 Threats

3.5 Y-O-Y Analyses

Chapter 4 Market Dynamics

4.1. Drivers

4.1.1 Models on Next-Gen Business

4.1.2 High growth in the prevalence of chronic diseases

4.1.3 Less cost biosimilar drugs

4.2 Restraints

4.2.1 High initial investment in research

4.2.2 Complexity in production

4.3 Opportunities

4.3.1 Emerging from biosimilar drugs

4.4 Challenges

4.4.1. Low cost compared to original products

Chapter 5 Asia Pacific Biosimilar Market – By Product

5.1 Insulin

5.2 Interferon

5.3 Human Growth Hormone

5.4 Granulocyte colony-stimulating factor

5.5 Others

Chapter 6 Asia Pacific Biosimilar Market – By Services

6.1 Clinical trials

6.2 Contract research & manufacturing services

Chapter 7 Asia Pacific Biosimilar Market – By Technology

7.1. Chromatography

7.2 Recombinant DNA Technology

7.3 Monoclonal Antibodies Technology

7.4 Nuclear magnetic resonance Technology

7.5 Others

Chapter 8 Asia Pacific Biosimilar Market – By Application

8.1 Oncology diseases

8.2 Chronic and autoimmune diseases

8.3 Blood disorders

8.4 Growth hormone deficiency

8.5 Others

Chapter 9 Asia Pacific Biosimilar Market – By Geography

9.1 Introduction

9.2 Asia Pacific

9.2.1.  China

9.2.2. Japan

9.2.3. India

9.2.4. South Korea

9.2.5. Australia & New Zealand

9.2.6. Rest of APAC

Chapter 10 Asia Pacific Biosimilar Market – Company Profiles

10.1. LG Life Sciences Limited

10.2. Teva Pharmaceuticals   

10.3. Celltrion

10.4. Hospira

10.5. Accord Healthcare

10.6. Hexal

10.7. Zydus Cadila Healthcare

10.8. Novartis/Sandoz

10.9. Apotex

10.10. Samsung Bioepis

10.11. Mylan

10.12. Eli Lilly

10.13. Harvest Moon Pharmaceuticals

10.14. Biocon

10.15. Bioxpress Therapeutics

Chapter 11 Asia Pacific Biosimilar Market – Competitive Landscape

11.1. Market Share Analysis

11.2. Strategies Adopted by top companies

11.3. Mergers, Acquisitions, Collaborations & Agreements

Chapter 12 Market Insights

12.1. Industry Experts Insights

12.2. Analysts Opinions

12.3. Investment Opportunities

Chapter 13 Appendix

13.1 List of Tables

13.2 List of Figures

  • Competitive Analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors.
  • Monitoring the external and internal factors which affect the market dynamics with the aid of PESTLE analysis.
  • The Regional and Global Variety is taken care of in the report.
  • Year on Year basis generation of revenue is studied.
  • Porter's Five Forces analyze the intensity of competition in an industry and its profitability level.
  • The overview and the sustainability of the market are analyzed through SWOT.
  • DROC is recognized in the current market scenario and see how its effect on market dynamics.
  • The segment-level analysis in terms of type and technology.
  • The value chain analysis, value that's created and captured by a company is the profit margin.Value
  • Created and Captured – Cost of Creating that Value = Margin
  • An executive summary consists of the whole report and the outcome is been given in the report to have brief knowledge about the report.
  • Basis on the depth of the study we approach using analytical tools
  • Expertise investment opportunities are given after analyzing the market to give the organization and the individual to have perfect knowledge about the market.


©2018 - Envision Inteligence | All Rights Reserved.